THE BEST DESIGNS
FOR THE MOST
STRATEGIC STUDIES
MEDSIR'S INNOVATION NOT DOES NOT ONLY INCLUDE THE OPTIMUM DESIGN OF THE RIGHT CLINICAL TRIAL, BUT ALSO THE MANNER IN WHICH CLINICAL RESEARCH IS IMPLEMENTED.
WE IMPROVE THE LIVES OF CANCER PATIENTS
THE MEDSIR CONCEPT OF PROVIDING A PLATFORM TO FACILITATE THE DEVELOPMENT OF IDEAS INTO STRATEGIC CLINICAL STUDY PROTOCOLS IS BECOMING MORE DIVERSE, INCORPORATING NOT ONLY NEW TUMOR TYPES, BUT ALSO MODERN AND INNOVATIVE TRIAL DESIGNS SUCH AS UMBRELLA AND MULTI-TUMOR BASKET TRIALS.
WORKING ON A NEW CLINICAL PROJECT WITH THE EXPECTATION THAT IT WILL HELP MANY PATIENTS IS EXHILARATING FOR MEDSIR, A JOB WELL DONE MEANS RESULTS THAT HAVE THE POTENTIAL TO CHANGE CLINICAL PRACTICE.
HERE YOU WILL FIND OUR COMPREHENSIVE PROJECT PORTFOLIO. PLEASE CONTACT US FOR FURTHER INFORMATION.
“LET´S CONVERT YOUR RESEARCH IDEA INTO A BRIGHTER FUTURE FOR CANCER PATIENTS”
POLEN
(GENITOURINARY TUMORS)
RESPONSE
(BREAST CANCER)
RESPONSE
(BREAST CANCER)
RESPONSE
(BREAST CANCER)
RESPONSE
(BREAST CANCER)
AZENT
(LUNG CANCER)
PATHFINDER
(BREAST CANCER)
PATHFINDER
(BREAST CANCER)
RESPONSE
(BREAST CANCER)
SLLIP
(LUNG CANCER)
PATHFINDER
(BREAST CANCER)
PATHFINDER
(BREAST CANCER)
PATHFINDER
(BREAST CANCER)
PATHFINDER
(BREAST CANCER)
DEBBRAH
(BREAST CANCER)
SLLIP
(LUNG CANCER)
METALLICA
(LUNG CANCER)
AZENT
(LUNG CANCER)
AZENT
(LUNG CANCER)
SLLIP
(LUNG CANCER)
SLLIP
(LUNG CANCER)
LUPER
(LUNG CANCER)
LUPER
(LUNG CANCER)
BRIDGE
(LUNG CANCER)
BRIDGE
(LUNG CANCER)
PECATI
(THYMIC CANCER)
PECATI
(THYMIC CANCER)
EXCAAPE
(GENITOURINARY TUMORS)
EXCAAPE
(GENITOURINARY TUMORS)
POLEN
(GENITOURINARY TUMORS)
POLEN
(GENITOURINARY TUMORS)
ZZFIRST
(GENITOURINARY TUMORS)
ZZFIRST
(GENITOURINARY TUMORS)
ORPHEUS
(GENITOURINARY TUMORS)
ORPHEUS
(GENITOURINARY TUMORS)
COPERNICO
(COVID-19)
COPERNICO
(COVID-19)
ASUNCTIS
(COVID-19)
ASUNCTIS
(COVID-19)
PHERGAIN-2
(BREAST CANCER)
PHERGAIN-2
(BREAST CANCER)
ABIGAIL
(BREAST CANCER)
ABIGAIL
(BREAST CANCER)
MEDSIR'S CLINICAL STUDIES
OPEN STUDIES
BIOPER
(BREAST CANCER)
BIOPER
(BREAST CANCER)
KELLY
(BREAST CANCER)
KELLY
(BREAST CANCER)
TRANSFAL
(BREAST CANCER)
TRANSFAL
(BREAST CANCER)
PHERGAIN
(BREAST CANCER)
PHERGAIN
(BREAST CANCER)
LUZERN
(BREAST CANCER)
LUZERN
(BREAST CANCER)
BARBICAN
(BREAST CANCER)
BARBICAN
(BREAST CANCER)
LINGAIN
(BREAST CANCER)
LINGAIN
(BREAST CANCER)
OPHELIA
(BREAST CANCER)
OPHELIA
(BREAST CANCER)
PIQUR
(BREAST CANCER)
PIQUR
(BREAST CANCER)
RESPONSE
(BREAST CANCER)
RESPONSE
(BREAST CANCER)
CALADRIO
(BREAST CANCER)
CALADRIO
(BREAST CANCER)
NOBROLA
(BREAST CANCER)
NOBROLA
(BREAST CANCER)
PALMIRA
(BREAST CANCER)
PALMIRA
(BREAST CANCER)
CAILA
(BREAST CANCER)
CAILA
(BREAST CANCER)
PATHFINDER
(BREAST CANCER)
PATHFINDER
(BREAST CANCER)
DXCARTES
(BREAST CANCER)
DXCARTES
(BREAST CANCER)
PARSIFAL
(BREAST CANCER)
PARSIFAL
(BREAST CANCER)
PHENOMENAL
(BREAST CANCER)
PHENOMENAL
(BREAST CANCER)
THELMA
(BREAST CANCER)
THELMA
(BREAST CANCER)
DEBBRAH
(BREAST CANCER)
DEBBRAH
(BREAST CANCER)
METALLICA
(BREAST CANCER)
METALLICA
(BREAST CANCER)
EXCAAPE
(GENITOURINARY TUMOURS)
EXCAAPE
(GENITOURINARY TUMOURS)
EXCAAPE
(GENITOURINARY TUMOURS)
EXCAAPE
(GENITOURINARY TUMOURS)
EXCAAPE
(GENITOURINARY TUMOURS)
ATRACTIB
(BREAST CANCER)
ATRACTIB
(BREAST CANCER)
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS OR ORAL PRESENTATIONS.
YEAR
CONGRESS
ABSTRACT (Posters, presentations, etc.)
PROJECT
EXCAAPE
a multicenter, single-arm, open-label, non-controlled phase IIa clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide.
ESMO
2020
KELLY
A phase II study of pembrolizumab and eribulin in patients with HRpositive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.
SABCS
2019
REVERT
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).
SABCS
2019
TRANSFAL
Prospective evaluation of predictive/prognostic biomarkers for palbociclib and endocrine therapy in ER positive HER2 negative advanced metastatic breast cancer within the PARSIFAL clinical trial.
SABCS
2019
PALMIRA
PALbociclib rechallenge in horMone receptor-posItive/HER2-negative Advanced breast cancer.
ESMO
2019
Other MEDSIR related articles